Green Light for Response: Clinical Stratification of Response to Biologic Therapy in Severe Asthma
Journal of Asthma and Allergy · 2026-02 · Volume 19 · 1-8
DOI: 10.2147/jaa.s577215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Asthma and Allergy, 2026-02. Verfasst von Raquel Lopez-Rodríguez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, Hospital Universitario Lucus Augusti, Lugo, Spain. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Biologic therapies have transformed the management of severe asthma; however, treatment response remains heterogeneous and difficult to anticipate in routine practice. Conventional biomarkers alone have limited ability to identify patients who will achieve complete or sustained clinical benefit. This study aimed to explore baseline clinical and inflammatory thresholds associated with response to biologic therapy and to propose an exploratory, clinically oriented stratification framework.
Methods
We conducted a secondary analysis of a real-world, single-center, ambispective cohort of adults with severe uncontrolled asthma treated with biologic therapies and followed for at least 12 months. Clinical response was assessed at 6 and 12 months using the multidimensional EXACTO and FEOS scales. Baseline clinical and biological variables were analyzed using exploratory ROC curve analyses to identify thresholds associated with complete clinical response.
Results
Among 64 patients, the proportion of complete responders increased from 14% at 6 months to 32.1% at 12 months. No significant differences in response were observed between biologic agents. Higher baseline blood eosinophil counts and a history of frequent exacerbations were associated with improved outcomes. Exploratory eosinophil thresholds of approximately 440 and 435 cells/µL were identified at 6 and 12 months, respectively. Female sex and nasal polyposis were also associated with higher response rates. Based on these findings, three exploratory response profiles reflecting different likelihoods of response were identified.
Conclusion
Baseline clinical and inflammatory characteristics may support response stratification in severe asthma. Given that maximal benefit may be achieved over longer treatment periods, extended follow-up should be considered before modifying biologic therapy. The proposed framework is exploratory and provides a basis for future prospective validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Allergy Department, Hospital Universitario Lucus Augusti, Lugo, Spain.
- Immunology Department, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain.
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
- Department of Biostatistics and Epidemiology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
- Department of Medicine, Universidad Autónoma de Madrid, CIBERES, Instituto de salud Carlos III, Madrid, Spain.
- Allergy Department, Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain.
ORCID-Profile: Manuel J Rial
Zitieren
APA
Lopez-Rodríguez, R., Cañas, J. A., Mahíllo-Fernández, I., & Rial, M. J. (2026). Green Light for Response: Clinical Stratification of Response to Biologic Therapy in Severe Asthma. Journal of Asthma and Allergy, Volume 19, 1-8. https://doi.org/10.2147/jaa.s577215
Vancouver
Lopez-Rodríguez R, Cañas JA, Mahíllo-Fernández I, Rial MJ. Green Light for Response: Clinical Stratification of Response to Biologic Therapy in Severe Asthma. Journal of Asthma and Allergy. 2026;Volume 19:1-8. doi:10.2147/jaa.s577215
BibTeX
@article{LopezRodrguez2026,
author = {Lopez-Rodríguez, Raquel and Cañas, José Antonio and Mahíllo-Fernández, Ignacio and Rial, Manuel J},
title = {Green Light for Response: Clinical Stratification of Response to Biologic Therapy in Severe Asthma},
journal = {Journal of Asthma and Allergy},
year = {2026},
volume = {Volume 19},
pages = {1--8},
doi = {10.2147/jaa.s577215}
}
EUVIMED